Market Overview:
The global bacterial vaginosis drug market is expected to grow at a CAGR of XX% during the forecast period from 2018 to 2030. The growth in this market can be attributed to the increasing prevalence of bacterial vaginosis, rising awareness about available treatment options, and growing demand for over-the-counter (OTC) drugs. Based on type, the global bacterial vaginosis drug market can be segmented into Rx and OTC drugs. The Rx segment is expected to account for a larger share of the market than the OTC segment during the forecast period. This can be attributed to factors such as high cost of prescription drugs and limited availability of these drugs in developing countries. However, with increasing awareness about available treatment options, the OTC segment is projected to grow at a higher CAGR than the Rx segment during the forecast period. Based on application, hospitals are expected to account for a larger share of the global bacterial vaginosis drug market than pharmacies and other applications during 2018–2030.
Product Definition:
A bacterial vaginosis drug is a medication that is used to treat bacterial vaginosis, a condition caused by an overgrowth of bacteria in the vagina. Bacterial vaginosis can cause symptoms such as abnormal vaginal discharge, odor, and itching. The importance of using a bacterial vaginosis drug to treat this condition is that it can help relieve these symptoms and restore the normal balance of bacteria in the vagina.
Rx:
Rx is short for prescription. It's a term used to define the medication given to a patient by the doctor. In case of BV, Rx is used for treating symptoms instead of looking at the root cause which may require surgical procedures in severe cases. The most common symptom that needs to be treated with drugs includes vaginal irritation and discharge. Other symptoms include lower abdominal pain, bloating or gassiness, frequent urination, and abnormal menstruation among others.
OTC:
OTC stands for Over-the-Counter and it is a category of drugs which can be used for the treatment of bacterial vaginosis (BV). Bacterial vaginosis is a vaginal infection caused by certain types of bacteria. The most common symptoms associated with this disease are abnormal vaginal discharge, itching, odor, and burning during urination.
Application Insights:
The other application segment includes health maintenance organizations and private practices. The global market for bacterial vaginosis drugs by other applications is expected to witness a CAGR of XX% from 2018 to 2030 owing to increasing awareness about the disease among general practitioners, resulting in increased usage of these drugs in their respective practices.
The hospital segment held the largest share of over 70% in 2017 and is also anticipated to be the fastest-growing segment during the forecast period due largely on factors such as rising prevalence rates and availability of high-quality generic medicines at dirt cheap prices that have resulted in an upsurge in demand for BV treatment across hospitals globally.
Regional Analysis:
North America dominated the global market in 2017. This can be attributed to high awareness levels, availability of improved treatment options, and a rise in the number of commercialized products for bacterial vaginosis treatment. In addition, increasing cases of sexually transmitted infections (STIs) are also contributing toward regional growth. For instance, according to statistics published by CDC National Center for Health Statistics (NCHS), in 2015 about 1 million new cases were reported among women aged 15-44 years which is approximately 0.6% of all females in this age group annually.
Asia Pacific is expected to witness lucrative growth over the forecast period owing to rising disposable income and improving healthcare infrastructure especially in developing countries such as India and China along with other South East Asian nations that have a large population base suffering from bacterial vaginosis or its precursor stages i.e., odor & discharge etc.
Growth Factors:
- Rising incidence of bacterial vaginosis (BV)
- Growing awareness about the symptoms and treatment of BV
- Increasing number of product launches by key players
- Rising demand for novel and effective treatments for BV
- Growing number of clinical studies on Bacterial Vaginosis Drugs
Scope Of The Report
Report Attributes
Report Details
Report Title
Bacterial Vaginosis Drug Market Research Report
By Type
Rx, OTC
By Application
Hospital, Pharmacy, Other
By Companies
Bayer, Pfizer, Sanofi, Piramal, Abbott, Galderma, Mission, Alkem, Xiuzheng, Teva, Perrigo, West-Ward, HPGC, Yunnan Baiyao, Starpharma, Novel, Edenvridge
Regions Covered
North America, Europe, APAC, Latin America, MEA
Base Year
2021
Historical Year
2019 to 2020 (Data from 2010 can be provided as per availability)
Forecast Year
2030
Number of Pages
211
Number of Tables & Figures
148
Customization Available
Yes, the report can be customized as per your need.
Global Bacterial Vaginosis Drug Market Report Segments:
The global Bacterial Vaginosis Drug market is segmented on the basis of:
Types
Rx, OTC
The product segment provides information about the market share of each product and the respective CAGR during the forecast period. It lays out information about the product pricing parameters, trends, and profits that provides in-depth insights of the market. Furthermore, it discusses latest product developments & innovation in the market.
Applications
Hospital, Pharmacy, Other
The application segment fragments various applications of the product and provides information on the market share and growth rate of each application segment. It discusses the potential future applications of the products and driving and restraining factors of each application segment.
Some of the companies that are profiled in this report are:
- Bayer
- Pfizer
- Sanofi
- Piramal
- Abbott
- Galderma
- Mission
- Alkem
- Xiuzheng
- Teva
- Perrigo
- West-Ward
- HPGC
- Yunnan Baiyao
- Starpharma
- Novel
- Edenvridge
Highlights of The Bacterial Vaginosis Drug Market Report:
- The market structure and projections for the coming years.
- Drivers, restraints, opportunities, and current trends of market.
- Historical data and forecast.
- Estimations for the forecast period 2030.
- Developments and trends in the market.
- By Type:
- Rx
- OTC
- By Application:
- Hospital
- Pharmacy
- Other
- Market scenario by region, sub-region, and country.
- Market share of the market players, company profiles, product specifications, SWOT analysis, and competitive landscape.
- Analysis regarding upstream raw materials, downstream demand, and current market dynamics.
- Government Policies, Macro & Micro economic factors are also included in the report.
We have studied the Bacterial Vaginosis Drug Market in 360 degrees via. both primary & secondary research methodologies. This helped us in building an understanding of the current market dynamics, supply-demand gap, pricing trends, product preferences, consumer patterns & so on. The findings were further validated through primary research with industry experts & opinion leaders across countries. The data is further compiled & validated through various market estimation & data validation methodologies. Further, we also have our in-house data forecasting model to predict market growth up to 2030.
Regional Analysis
- North America
- Europe
- Asia Pacific
- Middle East & Africa
- Latin America
Note: A country of choice can be added in the report at no extra cost. If more than one country needs to be added, the research quote will vary accordingly.
The geographical analysis part of the report provides information about the product sales in terms of volume and revenue in regions. It lays out potential opportunities for the new entrants, emerging players, and major players in the region. The regional analysis is done after considering the socio-economic factors and government regulations of the countries in the regions.
How you may use our products:
- Correctly Positioning New Products
- Market Entry Strategies
- Business Expansion Strategies
- Consumer Insights
- Understanding Competition Scenario
- Product & Brand Management
- Channel & Customer Management
- Identifying Appropriate Advertising Appeals
8 Reasons to Buy This Report
- Includes a Chapter on the Impact of COVID-19 Pandemic On the Market
- Report Prepared After Conducting Interviews with Industry Experts & Top Designates of the Companies in the Market
- Implemented Robust Methodology to Prepare the Report
- Includes Graphs, Statistics, Flowcharts, and Infographics to Save Time
- Industry Growth Insights Provides 24/5 Assistance Regarding the Doubts in the Report
- Provides Information About the Top-winning Strategies Implemented by Industry Players.
- In-depth Insights On the Market Drivers, Restraints, Opportunities, and Threats
- Customization of the Report Available
Frequently Asked Questions?
Bacterial vaginosis (BV) is a condition caused by an overgrowth of bacteria in the vagina. BV can cause irritation, discharge, and a fishy odor. Treatment typically includes antibiotics and douching.
Some of the key players operating in the bacterial vaginosis drug market are Bayer, Pfizer, Sanofi, Piramal, Abbott, Galderma, Mission, Alkem, Xiuzheng, Teva, Perrigo, West-Ward, HPGC, Yunnan Baiyao, Starpharma, Novel, Edenvridge.
Chapter 1 Executive Summary
Chapter 2 Assumptions and Acronyms Used
Chapter 3 Research Methodology
Chapter 4 Bacterial Vaginosis Drug Market Overview
4.1 Introduction
4.1.1 Market Taxonomy
4.1.2 Market Definition
4.1.3 Macro-Economic Factors Impacting the Market Growth
4.2 Bacterial Vaginosis Drug Market Dynamics
4.2.1 Market Drivers
4.2.2 Market Restraints
4.2.3 Market Opportunity
4.3 Bacterial Vaginosis Drug Market - Supply Chain Analysis
4.3.1 List of Key Suppliers
4.3.2 List of Key Distributors
4.3.3 List of Key Consumers
4.4 Key Forces Shaping the Bacterial Vaginosis Drug Market
4.4.1 Bargaining Power of Suppliers
4.4.2 Bargaining Power of Buyers
4.4.3 Threat of Substitution
4.4.4 Threat of New Entrants
4.4.5 Competitive Rivalry
4.5 Global Bacterial Vaginosis Drug Market Size & Forecast, 2020-2028
4.5.1 Bacterial Vaginosis Drug Market Size and Y-o-Y Growth
4.5.2 Bacterial Vaginosis Drug Market Absolute $ Opportunity
Chapter 5 Global Market Analysis and Forecast by Type
5.1 Introduction
5.1.1 Key Market Trends & Growth Opportunities by Type
5.1.2 Basis Point Share (BPS) Analysis by Type
5.1.3 Absolute $ Opportunity Assessment by Type
5.2 Market Size Forecast by Type
5.2.1 Rx
5.2.2 OTC
5.3 Market Attractiveness Analysis by Type
Chapter 6 Global Market Analysis and Forecast by Applications
6.1 Introduction
6.1.1 Key Market Trends & Growth Opportunities by Applications
6.1.2 Basis Point Share (BPS) Analysis by Applications
6.1.3 Absolute $ Opportunity Assessment by Applications
6.2 Market Size Forecast by Applications
6.2.1 Hospital
6.2.2 Pharmacy
6.2.3 Other
6.3 Market Attractiveness Analysis by Applications
Chapter 7 Global Bacterial Vaginosis Drug Market Analysis and Forecast by Region
7.1 Introduction
7.1.1 Key Market Trends & Growth Opportunities by Region
7.1.2 Basis Point Share (BPS) Analysis by Region
7.1.3 Absolute $ Opportunity Assessment by Region
7.2 Bacterial Vaginosis Drug Market Size Forecast by Region
7.2.1 North America
7.2.2 Europe
7.2.3 Asia Pacific
7.2.4 Latin America
7.2.5 Middle East & Africa (MEA)
7.3 Market Attractiveness Analysis by Region
Chapter 8 Coronavirus Disease (COVID-19) Impact
8.1 Introduction
8.2 Current & Future Impact Analysis
8.3 Economic Impact Analysis
8.4 Government Policies
8.5 Investment Scenario
Chapter 9 North America Analysis and Forecast
9.1 Introduction
9.2 North America Market Size Forecast by Country
9.2.1 U.S.
9.2.2 Canada
9.3 Basis Point Share (BPS) Analysis by Country
9.4 Absolute $ Opportunity Assessment by Country
9.5 Market Attractiveness Analysis by Country
9.6 North America Market Size Forecast by Type
9.6.1 Rx
9.6.2 OTC
9.7 Basis Point Share (BPS) Analysis by Type
9.8 Absolute $ Opportunity Assessment by Type
9.9 Market Attractiveness Analysis by Type
9.10 North America Market Size Forecast by Applications
9.10.1 Hospital
9.10.2 Pharmacy
9.10.3 Other
9.11 Basis Point Share (BPS) Analysis by Applications
9.12 Absolute $ Opportunity Assessment by Applications
9.13 Market Attractiveness Analysis by Applications
Chapter 10 Europe Analysis and Forecast
10.1 Introduction
10.2 Europe Market Size Forecast by Country
10.2.1 Germany
10.2.2 France
10.2.3 Italy
10.2.4 U.K.
10.2.5 Spain
10.2.6 Russia
10.2.7 Rest of Europe
10.3 Basis Point Share (BPS) Analysis by Country
10.4 Absolute $ Opportunity Assessment by Country
10.5 Market Attractiveness Analysis by Country
10.6 Europe Market Size Forecast by Type
10.6.1 Rx
10.6.2 OTC
10.7 Basis Point Share (BPS) Analysis by Type
10.8 Absolute $ Opportunity Assessment by Type
10.9 Market Attractiveness Analysis by Type
10.10 Europe Market Size Forecast by Applications
10.10.1 Hospital
10.10.2 Pharmacy
10.10.3 Other
10.11 Basis Point Share (BPS) Analysis by Applications
10.12 Absolute $ Opportunity Assessment by Applications
10.13 Market Attractiveness Analysis by Applications
Chapter 11 Asia Pacific Analysis and Forecast
11.1 Introduction
11.2 Asia Pacific Market Size Forecast by Country
11.2.1 China
11.2.2 Japan
11.2.3 South Korea
11.2.4 India
11.2.5 Australia
11.2.6 South East Asia (SEA)
11.2.7 Rest of Asia Pacific (APAC)
11.3 Basis Point Share (BPS) Analysis by Country
11.4 Absolute $ Opportunity Assessment by Country
11.5 Market Attractiveness Analysis by Country
11.6 Asia Pacific Market Size Forecast by Type
11.6.1 Rx
11.6.2 OTC
11.7 Basis Point Share (BPS) Analysis by Type
11.8 Absolute $ Opportunity Assessment by Type
11.9 Market Attractiveness Analysis by Type
11.10 Asia Pacific Market Size Forecast by Applications
11.10.1 Hospital
11.10.2 Pharmacy
11.10.3 Other
11.11 Basis Point Share (BPS) Analysis by Applications
11.12 Absolute $ Opportunity Assessment by Applications
11.13 Market Attractiveness Analysis by Applications
Chapter 12 Latin America Analysis and Forecast
12.1 Introduction
12.2 Latin America Market Size Forecast by Country
12.2.1 Brazil
12.2.2 Mexico
12.2.3 Rest of Latin America (LATAM)
12.3 Basis Point Share (BPS) Analysis by Country
12.4 Absolute $ Opportunity Assessment by Country
12.5 Market Attractiveness Analysis by Country
12.6 Latin America Market Size Forecast by Type
12.6.1 Rx
12.6.2 OTC
12.7 Basis Point Share (BPS) Analysis by Type
12.8 Absolute $ Opportunity Assessment by Type
12.9 Market Attractiveness Analysis by Type
12.10 Latin America Market Size Forecast by Applications
12.10.1 Hospital
12.10.2 Pharmacy
12.10.3 Other
12.11 Basis Point Share (BPS) Analysis by Applications
12.12 Absolute $ Opportunity Assessment by Applications
12.13 Market Attractiveness Analysis by Applications
Chapter 13 Middle East & Africa (MEA) Analysis and Forecast
13.1 Introduction
13.2 Middle East & Africa (MEA) Market Size Forecast by Country
13.2.1 Saudi Arabia
13.2.2 South Africa
13.2.3 UAE
13.2.4 Rest of Middle East & Africa (MEA)
13.3 Basis Point Share (BPS) Analysis by Country
13.4 Absolute $ Opportunity Assessment by Country
13.5 Market Attractiveness Analysis by Country
13.6 Middle East & Africa (MEA) Market Size Forecast by Type
13.6.1 Rx
13.6.2 OTC
13.7 Basis Point Share (BPS) Analysis by Type
13.8 Absolute $ Opportunity Assessment by Type
13.9 Market Attractiveness Analysis by Type
13.10 Middle East & Africa (MEA) Market Size Forecast by Applications
13.10.1 Hospital
13.10.2 Pharmacy
13.10.3 Other
13.11 Basis Point Share (BPS) Analysis by Applications
13.12 Absolute $ Opportunity Assessment by Applications
13.13 Market Attractiveness Analysis by Applications
Chapter 14 Competition Landscape
14.1 Bacterial Vaginosis Drug Market: Competitive Dashboard
14.2 Global Bacterial Vaginosis Drug Market: Market Share Analysis, 2019
14.3 Company Profiles (Details – Overview, Financials, Developments, Strategy)
14.3.1 Bayer
14.3.2 Pfizer
14.3.3 Sanofi
14.3.4 Piramal
14.3.5 Abbott
14.3.6 Galderma
14.3.7 Mission
14.3.8 Alkem
14.3.9 Xiuzheng
14.3.10 Teva
14.3.11 Perrigo
14.3.12 West-Ward
14.3.13 HPGC
14.3.14 Yunnan Baiyao
14.3.15 Starpharma
14.3.16 Novel
14.3.17 Edenvridge
